新闻通稿

/新闻通稿

Oramed to Present at the Tides Europe 2018 Conference

NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Tides Europe 2018 Conference, EuroPeptides Track, taking [...]

2018-11-05T08:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at Cardiometabolic Health Congress

NEW YORK, Oct. 23, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing two recent Phase IIb studies of its orally ingestible insulin capsule, [...]

2018-10-23T08:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at the H.C. Wainwright Global Investment Conference

NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright 20th Annual Global Investment Conference, [...]

2018-08-28T08:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Granted Japanese Patent for GLP-1 Analog Capsule

NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent [...]

2018-07-24T08:26:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Announces Closing of $18.1 Million Registered Direct Offering

NEW YORK, July 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the closing of its previously-announced registered direct offering with several healthcare-focused institutional investors. Oramed has sold $18.1 [...]

2018-07-06T17:00:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Announces $18.1 Million Registered Direct Offering

NEW YORK, July 3, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase in [...]

2018-07-03T01:49:00+00:00 Categories: 新闻通稿|Tags: |